Aurora BioPharma, Inc. CEO Meets with Investors at The Family Office Super Summit
CAMBRIDGE, MA - December 1, 2015 - Aurora BioPharma, Inc. announces its CEO, Robert Brooks, will attend The Family Office Super Summit taking place December 1 - 2, 2015 at the JW Marriott Hotel on Brickell Avenue in Miami, Florida. Attendees will join hundreds of private wealth managers, family office executives, and dealmakers for the two-day gathering featuring over 60 speakers. The day is devoted to $1B+ family offices, dozens of single family offices, and hundreds of delegates.
About Aurora BioPharma, Inc.
Aurora is a biotechnology company based in Cambridge, Massachusetts commercializing cutting-edge cancer immunotherapy drugs in FDA human clinical trials. The Company is one of a handful of companies with Chimeric Antigen Receptor T-cell therapy (CAR T) in clinical trials in solid tumor, and pre-clinical trials in liquid and solid tumor. The Company is planning its CAR T cell agent AU-105, a randomized multisite Phase II Glioblastoma trial, and a Phase I intracranial injection trial. Aurora's team is comprised of experienced research scientists and business professionals with successful track records in the industry.
About Wilson Conferences
Wilson Conferences hosts dozens of annual investment conferences around the world at upscale venues such as Harvard Club, InterContinental Hotels and Resorts, Raffles Hotels and Resorts, and JW Marriott Hotels. The business operates the largest family office association and top media assets.
Cautionary Note on Forward-Looking Statements
This press release and any statements of representatives and partners of Aurora BioPharma, Inc. (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the U.S. federal securities laws. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors, many of which are beyond the Company's control. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
For media inquiries, please contact:
VP, Business Development & Public Relations
Aurora BioPharma, Inc.
Harvard Square, One Mifflin Place, Suite 400
Cambridge, MA 02138
Tel: 617-674-7718 - Fax: 617-674-7701
Ingraham Building, 25 SE 2nd Avenue, Suite 504
Miami, FL 33131
Tel: 305-371-2301 - Fax: 305-371-2301
firstname.lastname@example.org - www.aurorabiopharma.net
- New Paradigm in Cancer Immunotherapy –
Source: Aurora BioPharma, Inc.